No Data
No Data
Express News | The European Medicines Agency Has Validated The Submission Of KalVista Pharmaceuticals' Marketing Application Seeking Approval For Sebetralstat For The On-demand Treatment Of Hereditary Angioedema
Express News | Kalvista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $39
No Data